Legal & General Group
LXEO icon

Legal & General Group’s Lexeo Therapeutics LXEO Stock Holding History

Legal & General Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.3K Hold
5,631
– – ﹤0.01% 2807
2025
Q4 		$55.9K Buy
5,631
+3,599
+177% +$32.8K ﹤0.01% 2708
2025
Q3 		$13.5K Hold
2,032
– – ﹤0.01% 3204
2025
Q2 		$8.17K Sell
2,032
-495
-20% -$1.63K ﹤0.01% 3336
2025
Q1 		$8.77K Hold
2,527
– – ﹤0.01% 3202
2024
Q4 		$16.6K Hold
2,527
– – ﹤0.01% 3092
2024
Q3 		$22.8K Buy
2,527
+1,517
+150% +$18.1K ﹤0.01% 3001
2024
Q2 		$16.2K Buy
1,010
+147
+17% +$2.13K ﹤0.01% 3113
2024
Q1 		$13.5K Sell
863
-14,137
-94% -$221K ﹤0.01% 3128
2023
Q4 		$202K Buy
+15,000
New +$186K ﹤0.01% 2695

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's LXEO Position: Q1 2026 in Review

Legal & General Group held its Lexeo Therapeutics (LXEO) position steady in Q1 2026 at 5,631 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.

Legal & General Group first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $202K in Q4 2023. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Legal & General Group held 5,631 shares of Lexeo Therapeutics worth $32.3K as of Q1 2026.
  • Legal & General Group left its Lexeo Therapeutics share count unchanged in Q1 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2807 holding.
  • Legal & General Group first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Legal & General Group's Lexeo Therapeutics position peaked at $202K in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.